(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 123.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.68%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.49%.
Verastem's revenue in 2026 is $30,914,000.On average, 11 Wall Street analysts forecast VSTM's revenue for 2026 to be $9,617,065,756, with the lowest VSTM revenue forecast at $5,732,821,698, and the highest VSTM revenue forecast at $14,083,480,896. On average, 10 Wall Street analysts forecast VSTM's revenue for 2027 to be $19,175,281,991, with the lowest VSTM revenue forecast at $12,086,110,586, and the highest VSTM revenue forecast at $30,130,954,762.
In 2028, VSTM is forecast to generate $30,654,451,994 in revenue, with the lowest revenue forecast at $20,099,307,306 and the highest revenue forecast at $43,540,740,395.